5 results about "Olanzapine" patented technology

The invention relates to the technical field of drug detection, in particular to a molecularly imprinted sensor for quantitatively detecting olanzapine in human blood as well as a preparation method and application of the molecularly imprinted sensor. Au-Pt NSF is deposited on the surface of a substrate electrode through an HBDT method, then a molecularly imprinted polyaniline layer is prepared through electro-polymerization, and the molecularly imprinted sensor is formed. A classical redox probe potassium hexacyanoferrate is used as a tool, and DPV is used for monitoring current change (delta I) caused by olanzapine addition, so that sensitive quantitative detection of olanzapine is realized. The sensor prepared by the invention shows a good linear relationship to olanzapine in the concentration ranges of 0.005-0.4 mu M and 0.4-10 mu M, the detection limit is 0.94 nM, and the sensor has high reproducibility and stability (relative standard deviation RSDlt;

This invention discloses the application of catalpol in the preparation of drugs for the prevention and treatment of schizophrenia and the alleviation of the glucose and lipid metabolism side effects of olanzapine. Using a schizophrenia model mouse model induced by the commonly used MK801, the therapeutic effect of catalpol on schizophrenia was investigated, and the therapeutic effect of catalpol on the glucose and lipid metabolism side effects of the commonly used drug olanzapine was investigated through long-term gavage administration. A systematic study of catalpol was conducted from pharmacodynamic, behavioral, and morphological perspectives. The results showed that catalpol effectively improved the behavioral characteristics of the schizophrenia model mice, alleviated negative symptoms and cognitive impairment; catalpol effectively improved olanzapine-induced obesity and lipid metabolism disorders. This provides a theoretical research basis for the development of catalpol into a drug for the treatment of schizophrenia.

The application discloses a kind of HPLC-MSMS method for simultaneously determining valproic acid, olanzapine and its metabolites in plasma, which comprises the following steps: S1. pretreatment of plasma samples with acetonitrile protein precipitation method;S2. HPLC-MSMS method is used to detect plasma samples, and qualitative and / or quantitative analysis of valproic acid, olanzapine and its metabolites in plasma is carried out simultaneously;Wherein, Agilent Poroshell 120EC-C18 column is selected as the chromatographic column;Electrospray ion source is used, and the mobile phase is A phase: formic acid water, B phase: acetonitrile;By optimizing the conditions of liquid phase and mass spectrometry, valproic acid, olanzapine and its metabolites are simultaneously determined by one method.The method has been applied to detect plasma samples of olanzapine and valproic acid combination, and olanzapine alone, and the measured results all meet the linear range.

The invention relates to an olanzapine immunodetection reagent as well as a preparation method and a detection method thereof, in particular to an olanzapine chemiluminescence immunodetection reagent as well as a preparation method and a detection method thereof, and the olanzapine chemiluminescence immunodetection reagent comprises an anti-olanzapine specific antibody and an indicating reagent for detecting an anti-olanzapine specific antibody-olanzapine conjugate, the anti-olanzapine specific antibody is obtained by immunizing animals with olanzapine immunogen. The olanzapine immunogen has the beneficial effects that the olanzapine immunogen has strong specificity and high immunogenicity, and the prepared olanzapine specific antibody has strong specificity and high titer; a chemiluminescence immunoassay reagent containing the anti-olanzapine specific antibody can conveniently, quickly and accurately determine the olanzapine content in a sample, can simultaneously determine a plurality of samples on a full-automatic chemiluminescence immunoassay instrument, realizes high-flux quick determination of olanzapine, and is high in accuracy, strong in specificity and high in sensitivity. And the accuracy and the detection efficiency are greatly improved.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors in combination with a Compound of Formula VIII or a Compound of Formula IX, as described herein, or in combination with an antiemetic agent, such as an antipsychotic agent, e.g., olanzapine, for preventing or treating nausea and / or vomiting, e.g., CINV (chemotherapy-induced nausea and vomiting). In some embodiments, the Compound of Formula VIII or the Compound of Formula IX is used as mono-therapy (i.e., without a PDE1 inhibitor).